Human adipose tissue-derived mesenchymal stem cells protect kidneys from cisplatin nephrotoxicity in rats.
Kim JH., Park DJ., Yun JC., Jung MH., Yeo HD., Kim HJ.
Prospective Study on Acute Kidney Injury, published in Am J Physiol Renal Physiol (2012) — summary generated from the PubMed abstract.
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Am J Physiol Renal Physiol (2012)
- Country
- United States
- Reported sample size
- —
- PMID
- 22205231
- DOI
- 10.1152/ajprenal.00060.2011
Abstract (original English)
Cisplatin has multiple cellular targets and modes of action that lead to nephrotoxicity. This suggests novel therapies that act at multiple cisplatin target sites may be effective. We tested whether human adipose tissue-derived mesenchymal stem cells (Ad-MSCs) can affect multiple target sites and protect against cisplatin-induced kidney damage. Rats were divided into four groups: control, infused with Ad-MSCs, injected with cisplatin, and cisplatin followed by infusion of Ad-MSCs. Animal survival and renal function were decreased and histological damage was increased in cisplatin-treated rats at day 3. Infusion of Ad-MSCs ameliorated renal dysfunction and tissue injury caused by cisplatin, leading to increased survival. Apoptotic cell death in the kidney was significantly reduced by infusion of Ad-MSCs. Activation of p53, JNK, and ERK and the expression of inflammation-related molecules were also decreased in the kidney that received Ad-MSCs. Very few Ad-MSCs were detected in the kidney. Conditioned medium from cultured Ad-MSCs had renal-protective functions in vivo and in vitro. Renal dysfunction and tissue damage caused by cisplatin were significantly reduced in rats treated with Ad-MSCs-conditioned medium. The viability of cultured renal proximal tubular cells exposed to cisplatin was also improved by coculture with Ad-MSCs or with conditioned medium. Release of proinflammat
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples, often without a control group.
How we grade evidenceRelated research
- Level ASystematic Review
Concise Review: Using Fat to Fight Disease: A Systematic Review of Nonhomologous Adipose-Derived Stromal/Stem Cell Therapies.
Systematic Review on Osteoarthritis, Acute Kidney Injury, Cardiovascular Disease, Stroke Research, published in Stem Cells (2018) — summary generated from the PubMed abstract.
- 2018
Stem Cells - Level BRandomized Controlled Trial
Efficacy of allogeneic mesenchymal stem cell administration in a model of acute ischemic kidney injury in cats.
Randomized Controlled Trial with a reported sample of 15 on Acute Kidney Injury, published in Res Vet Sci (2016) — summary generated from the PubMed abstract.
- 2016
- n = 15
Res Vet Sci - Level CProspective Study
Charge-reversed small extracellular vesicles from human adipose-derived mesenchymal stromal cells attenuate renal fibrosis postacute kidney injury by inhibiting epithelial-mesenchymal transition progression in SD rat mod
Prospective Study on Chronic Kidney Disease, Acute Kidney Injury, published in Cytotherapy (2025) — summary generated from the PubMed abstract.
- 2025
Cytotherapy - Level CProspective Study
Rapid recovery of male cats with postrenal acute kidney injury by treating with allogeneic adipose mesenchymal stem cell-derived extracellular vesicles.
Prospective Study on Acute Kidney Injury, published in Stem Cell Res Ther (2022) — summary generated from the PubMed abstract.
- 2022
Stem Cell Res Ther - Level CProspective Study
Reproducible Large-Scale Isolation of Exosomes from Adipose Tissue-Derived Mesenchymal Stem/Stromal Cells and Their Application in Acute Kidney Injury.
Prospective Study on Chronic Kidney Disease, Acute Kidney Injury, published in Int J Mol Sci (2020) — summary generated from the PubMed abstract.
- 2020
Int J Mol Sci - Level CProspective Study
Renal Vein Levels of MicroRNA-26a Are Lower in the Poststenotic Kidney.
Prospective Study with a reported sample of 7 on Acute Kidney Injury, published in J Am Soc Nephrol (2015) — summary generated from the PubMed abstract.
- 2015
- n = 7
J Am Soc Nephrol